nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—Buclizine—Imatinib—hematologic cancer	0.16	0.524	CrCrCtD
Loperamide—Meclizine—Imatinib—hematologic cancer	0.145	0.476	CrCrCtD
Loperamide—ABCB1—hematologic cancer	0.0591	1	CbGaD
Loperamide—CYP2B6—Thiotepa—hematologic cancer	0.0213	0.0604	CbGbCtD
Loperamide—ABCB1—Lenalidomide—hematologic cancer	0.0132	0.0374	CbGbCtD
Loperamide—CYP2B6—Ifosfamide—hematologic cancer	0.0121	0.0343	CbGbCtD
Loperamide—CYP2C8—Bortezomib—hematologic cancer	0.0119	0.0338	CbGbCtD
Loperamide—CYP2D6—Lomustine—hematologic cancer	0.0115	0.0327	CbGbCtD
Loperamide—CYP2B6—Nilotinib—hematologic cancer	0.0105	0.0298	CbGbCtD
Loperamide—CYP2D6—Idarubicin—hematologic cancer	0.0103	0.0292	CbGbCtD
Loperamide—CYP2C8—Ifosfamide—hematologic cancer	0.00915	0.026	CbGbCtD
Loperamide—CYP2D6—Hydroxyurea—hematologic cancer	0.00875	0.0248	CbGbCtD
Loperamide—CYP2C8—Nilotinib—hematologic cancer	0.00794	0.0225	CbGbCtD
Loperamide—CYP3A4—Bexarotene—hematologic cancer	0.00789	0.0224	CbGbCtD
Loperamide—ABCB1—Daunorubicin—hematologic cancer	0.00772	0.0219	CbGbCtD
Loperamide—CYP2D6—Bortezomib—hematologic cancer	0.00761	0.0216	CbGbCtD
Loperamide—ABCB1—Alitretinoin—hematologic cancer	0.00757	0.0215	CbGbCtD
Loperamide—CYP3A4—Busulfan—hematologic cancer	0.00734	0.0208	CbGbCtD
Loperamide—CYP3A4—Lomustine—hematologic cancer	0.00734	0.0208	CbGbCtD
Loperamide—CYP2B6—Irinotecan—hematologic cancer	0.00721	0.0205	CbGbCtD
Loperamide—CYP3A4—Thiotepa—hematologic cancer	0.00654	0.0186	CbGbCtD
Loperamide—ABCB1—Imatinib—hematologic cancer	0.00592	0.0168	CbGbCtD
Loperamide—CYP2B6—Cisplatin—hematologic cancer	0.00588	0.0167	CbGbCtD
Loperamide—CYP2D6—Imatinib—hematologic cancer	0.00557	0.0158	CbGbCtD
Loperamide—ABCB1—Nilotinib—hematologic cancer	0.00538	0.0153	CbGbCtD
Loperamide—ABCB1—Vinorelbine—hematologic cancer	0.00533	0.0151	CbGbCtD
Loperamide—CYP3A4—Methoxsalen—hematologic cancer	0.00509	0.0144	CbGbCtD
Loperamide—CYP2D6—Nilotinib—hematologic cancer	0.00507	0.0144	CbGbCtD
Loperamide—CYP2D6—Vinorelbine—hematologic cancer	0.00502	0.0143	CbGbCtD
Loperamide—CYP3A4—Bortezomib—hematologic cancer	0.00484	0.0137	CbGbCtD
Loperamide—ABCB1—Dasatinib—hematologic cancer	0.00475	0.0135	CbGbCtD
Loperamide—CYP2B6—Dexamethasone—hematologic cancer	0.00475	0.0135	CbGbCtD
Loperamide—ABCB1—Mitoxantrone—hematologic cancer	0.00469	0.0133	CbGbCtD
Loperamide—CYP3A4—Daunorubicin—hematologic cancer	0.00463	0.0131	CbGbCtD
Loperamide—CYP2C8—Etoposide—hematologic cancer	0.00437	0.0124	CbGbCtD
Loperamide—ABCB1—Betamethasone—hematologic cancer	0.00418	0.0119	CbGbCtD
Loperamide—ABCB1—Gemcitabine—hematologic cancer	0.00415	0.0118	CbGbCtD
Loperamide—ABCB1—Prednisolone—hematologic cancer	0.00413	0.0117	CbGbCtD
Loperamide—CYP3A4—Cytarabine—hematologic cancer	0.00408	0.0116	CbGbCtD
Loperamide—CYP3A4—Teniposide—hematologic cancer	0.00402	0.0114	CbGbCtD
Loperamide—CYP2B6—Doxorubicin—hematologic cancer	0.00394	0.0112	CbGbCtD
Loperamide—ABCB1—Prednisone—hematologic cancer	0.0039	0.0111	CbGbCtD
Loperamide—CYP3A4—Ifosfamide—hematologic cancer	0.00371	0.0105	CbGbCtD
Loperamide—ABCB1—Irinotecan—hematologic cancer	0.0037	0.0105	CbGbCtD
Loperamide—CYP2C8—Dexamethasone—hematologic cancer	0.0036	0.0102	CbGbCtD
Loperamide—CYP3A4—Imatinib—hematologic cancer	0.00354	0.0101	CbGbCtD
Loperamide—CYP3A4—Ruxolitinib—hematologic cancer	0.00334	0.00947	CbGbCtD
Loperamide—ABCB1—Vinblastine—hematologic cancer	0.00329	0.00932	CbGbCtD
Loperamide—ABCB1—Vincristine—hematologic cancer	0.00323	0.00916	CbGbCtD
Loperamide—CYP3A4—Nilotinib—hematologic cancer	0.00322	0.00914	CbGbCtD
Loperamide—CYP3A4—Vinorelbine—hematologic cancer	0.00319	0.00906	CbGbCtD
Loperamide—CYP2D6—Vinblastine—hematologic cancer	0.0031	0.00878	CbGbCtD
Loperamide—ABCB1—Cisplatin—hematologic cancer	0.00301	0.00855	CbGbCtD
Loperamide—ABCB1—Etoposide—hematologic cancer	0.00296	0.0084	CbGbCtD
Loperamide—CYP3A4—Triamcinolone—hematologic cancer	0.00292	0.00829	CbGbCtD
Loperamide—CYP3A4—Dasatinib—hematologic cancer	0.00285	0.00808	CbGbCtD
Loperamide—CYP3A4—Mitoxantrone—hematologic cancer	0.00281	0.00798	CbGbCtD
Loperamide—POMC—hematopoietic system—hematologic cancer	0.00271	0.0934	CbGeAlD
Loperamide—CYP3A4—Betamethasone—hematologic cancer	0.00251	0.00711	CbGbCtD
Loperamide—CYP3A4—Prednisolone—hematologic cancer	0.00247	0.00702	CbGbCtD
Loperamide—ABCB1—Dexamethasone—hematologic cancer	0.00243	0.0069	CbGbCtD
Loperamide—CYP3A4—Prednisone—hematologic cancer	0.00234	0.00663	CbGbCtD
Loperamide—CYP2D6—Dexamethasone—hematologic cancer	0.00229	0.00651	CbGbCtD
Loperamide—CYP3A4—Irinotecan—hematologic cancer	0.00221	0.00628	CbGbCtD
Loperamide—POMC—gonad—hematologic cancer	0.00206	0.0711	CbGeAlD
Loperamide—ABCB1—Doxorubicin—hematologic cancer	0.00202	0.00573	CbGbCtD
Loperamide—CYP3A4—Vinblastine—hematologic cancer	0.00197	0.00559	CbGbCtD
Loperamide—ABCB1—Methotrexate—hematologic cancer	0.00196	0.00555	CbGbCtD
Loperamide—CYP3A4—Vincristine—hematologic cancer	0.00194	0.00549	CbGbCtD
Loperamide—CYP2D6—Doxorubicin—hematologic cancer	0.0019	0.0054	CbGbCtD
Loperamide—POMC—blood—hematologic cancer	0.00179	0.0619	CbGeAlD
Loperamide—CYP3A4—Etoposide—hematologic cancer	0.00177	0.00503	CbGbCtD
Loperamide—POMC—lung—hematologic cancer	0.00157	0.0543	CbGeAlD
Loperamide—POMC—testis—hematologic cancer	0.00148	0.0512	CbGeAlD
Loperamide—CYP3A4—Dexamethasone—hematologic cancer	0.00146	0.00414	CbGbCtD
Loperamide—CACNA1A—testis—hematologic cancer	0.00142	0.0489	CbGeAlD
Loperamide—CYP3A4—Doxorubicin—hematologic cancer	0.00121	0.00343	CbGbCtD
Loperamide—OPRM1—hematopoietic system—hematologic cancer	0.00102	0.0352	CbGeAlD
Loperamide—CALM2—hematopoietic system—hematologic cancer	0.000739	0.0255	CbGeAlD
Loperamide—CALM1—hematopoietic system—hematologic cancer	0.000736	0.0254	CbGeAlD
Loperamide—OPRM1—blood—hematologic cancer	0.000675	0.0233	CbGeAlD
Loperamide—CALM3—blood—hematologic cancer	0.000623	0.0215	CbGeAlD
Loperamide—CYP2C8—hematopoietic system—hematologic cancer	0.000612	0.0212	CbGeAlD
Loperamide—CALM3—bone marrow—hematologic cancer	0.000603	0.0208	CbGeAlD
Loperamide—CALM2—gonad—hematologic cancer	0.000562	0.0194	CbGeAlD
Loperamide—CALM1—gonad—hematologic cancer	0.000559	0.0193	CbGeAlD
Loperamide—OPRM1—testis—hematologic cancer	0.000558	0.0193	CbGeAlD
Loperamide—CYP2B6—hematopoietic system—hematologic cancer	0.000549	0.019	CbGeAlD
Loperamide—CALM3—lung—hematologic cancer	0.000546	0.0189	CbGeAlD
Loperamide—CALM3—testis—hematologic cancer	0.000516	0.0178	CbGeAlD
Loperamide—CALM2—blood—hematologic cancer	0.00049	0.0169	CbGeAlD
Loperamide—CALM1—blood—hematologic cancer	0.000487	0.0168	CbGeAlD
Loperamide—CALM2—bone marrow—hematologic cancer	0.000474	0.0164	CbGeAlD
Loperamide—CALM1—bone marrow—hematologic cancer	0.000472	0.0163	CbGeAlD
Loperamide—CALM2—lung—hematologic cancer	0.000429	0.0148	CbGeAlD
Loperamide—CALM1—lung—hematologic cancer	0.000427	0.0148	CbGeAlD
Loperamide—Haloperidol—H1F0—hematologic cancer	0.000424	0.327	CrCbGaD
Loperamide—CYP2B6—gonad—hematologic cancer	0.000418	0.0144	CbGeAlD
Loperamide—CYP3A4—hematopoietic system—hematologic cancer	0.000415	0.0143	CbGeAlD
Loperamide—CYP2D6—hematopoietic system—hematologic cancer	0.000408	0.0141	CbGeAlD
Loperamide—CYP2C8—blood—hematologic cancer	0.000406	0.014	CbGeAlD
Loperamide—CALM2—testis—hematologic cancer	0.000405	0.014	CbGeAlD
Loperamide—CALM1—testis—hematologic cancer	0.000403	0.0139	CbGeAlD
Loperamide—CALM3—lymph node—hematologic cancer	0.000374	0.0129	CbGeAlD
Loperamide—CYP2B6—blood—hematologic cancer	0.000364	0.0126	CbGeAlD
Loperamide—CYP2C8—testis—hematologic cancer	0.000336	0.0116	CbGeAlD
Loperamide—CYP2B6—lung—hematologic cancer	0.000319	0.011	CbGeAlD
Loperamide—CYP2B6—testis—hematologic cancer	0.000301	0.0104	CbGeAlD
Loperamide—ABCB1—hematopoietic system—hematologic cancer	0.000294	0.0101	CbGeAlD
Loperamide—CALM2—lymph node—hematologic cancer	0.000294	0.0101	CbGeAlD
Loperamide—CALM1—lymph node—hematologic cancer	0.000292	0.0101	CbGeAlD
Loperamide—CYP3A4—blood—hematologic cancer	0.000275	0.00949	CbGeAlD
Loperamide—CYP2D6—blood—hematologic cancer	0.00027	0.00934	CbGeAlD
Loperamide—Clotrimazole—ABCC3—hematologic cancer	0.000241	0.186	CrCbGaD
Loperamide—CYP2D6—testis—hematologic cancer	0.000224	0.00773	CbGeAlD
Loperamide—ABCB1—gonad—hematologic cancer	0.000223	0.00771	CbGeAlD
Loperamide—ABCB1—blood—hematologic cancer	0.000195	0.00672	CbGeAlD
Loperamide—ABCB1—bone marrow—hematologic cancer	0.000188	0.0065	CbGeAlD
Loperamide—ABCB1—lung—hematologic cancer	0.000171	0.00589	CbGeAlD
Loperamide—Toremifene—ESR1—hematologic cancer	0.000169	0.131	CrCbGaD
Loperamide—ABCB1—testis—hematologic cancer	0.000161	0.00556	CbGeAlD
Loperamide—ABCB1—lymph node—hematologic cancer	0.000117	0.00403	CbGeAlD
Loperamide—Toremifene—ABCB1—hematologic cancer	7.2e-05	0.0555	CrCbGaD
Loperamide—Tamoxifen—ABCG2—hematologic cancer	6.91e-05	0.0533	CrCbGaD
Loperamide—Tamoxifen—ESR1—hematologic cancer	6.77e-05	0.0522	CrCbGaD
Loperamide—Fexofenadine—ABCB1—hematologic cancer	6.29e-05	0.0485	CrCbGaD
Loperamide—Drowsiness—Epirubicin—hematologic cancer	5.65e-05	0.000437	CcSEcCtD
Loperamide—Rash—Thiotepa—hematologic cancer	5.64e-05	0.000437	CcSEcCtD
Loperamide—Dermatitis—Thiotepa—hematologic cancer	5.64e-05	0.000436	CcSEcCtD
Loperamide—Diarrhoea—Alitretinoin—hematologic cancer	5.63e-05	0.000436	CcSEcCtD
Loperamide—Headache—Thiotepa—hematologic cancer	5.61e-05	0.000434	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Epirubicin—hematologic cancer	5.6e-05	0.000434	CcSEcCtD
Loperamide—Diarrhoea—Ifosfamide—hematologic cancer	5.57e-05	0.000431	CcSEcCtD
Loperamide—Nausea—Vinorelbine—hematologic cancer	5.57e-05	0.000431	CcSEcCtD
Loperamide—Gastrointestinal disorder—Etoposide—hematologic cancer	5.55e-05	0.00043	CcSEcCtD
Loperamide—Asthenia—Irinotecan—hematologic cancer	5.54e-05	0.000429	CcSEcCtD
Loperamide—Asthenia—Mitoxantrone—hematologic cancer	5.54e-05	0.000429	CcSEcCtD
Loperamide—Fatigue—Etoposide—hematologic cancer	5.54e-05	0.000429	CcSEcCtD
Loperamide—Vomiting—Thalidomide—hematologic cancer	5.5e-05	0.000426	CcSEcCtD
Loperamide—Dizziness—Carmustine—hematologic cancer	5.5e-05	0.000426	CcSEcCtD
Loperamide—Constipation—Etoposide—hematologic cancer	5.5e-05	0.000426	CcSEcCtD
Loperamide—Rash—Thalidomide—hematologic cancer	5.46e-05	0.000423	CcSEcCtD
Loperamide—Discomfort—Dexamethasone—hematologic cancer	5.45e-05	0.000422	CcSEcCtD
Loperamide—Discomfort—Betamethasone—hematologic cancer	5.45e-05	0.000422	CcSEcCtD
Loperamide—Dermatitis—Thalidomide—hematologic cancer	5.45e-05	0.000422	CcSEcCtD
Loperamide—Dizziness—Alitretinoin—hematologic cancer	5.45e-05	0.000422	CcSEcCtD
Loperamide—Diarrhoea—Vincristine—hematologic cancer	5.43e-05	0.00042	CcSEcCtD
Loperamide—Headache—Thalidomide—hematologic cancer	5.42e-05	0.00042	CcSEcCtD
Loperamide—Asthenia—Gemcitabine—hematologic cancer	5.4e-05	0.000418	CcSEcCtD
Loperamide—Dizziness—Ifosfamide—hematologic cancer	5.38e-05	0.000417	CcSEcCtD
Loperamide—Urinary tract disorder—Methotrexate—hematologic cancer	5.35e-05	0.000414	CcSEcCtD
Loperamide—Pruritus—Gemcitabine—hematologic cancer	5.33e-05	0.000412	CcSEcCtD
Loperamide—Nausea—Thiotepa—hematologic cancer	5.32e-05	0.000412	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—hematologic cancer	5.31e-05	0.000411	CcSEcCtD
Loperamide—Anaphylactic shock—Dexamethasone—hematologic cancer	5.29e-05	0.00041	CcSEcCtD
Loperamide—Anaphylactic shock—Betamethasone—hematologic cancer	5.29e-05	0.00041	CcSEcCtD
Loperamide—Diarrhoea—Mitoxantrone—hematologic cancer	5.29e-05	0.000409	CcSEcCtD
Loperamide—Diarrhoea—Irinotecan—hematologic cancer	5.29e-05	0.000409	CcSEcCtD
Loperamide—Vomiting—Carmustine—hematologic cancer	5.28e-05	0.000409	CcSEcCtD
Loperamide—Gastrointestinal pain—Etoposide—hematologic cancer	5.26e-05	0.000407	CcSEcCtD
Loperamide—Dizziness—Vincristine—hematologic cancer	5.25e-05	0.000406	CcSEcCtD
Loperamide—Rash—Carmustine—hematologic cancer	5.24e-05	0.000406	CcSEcCtD
Loperamide—Dermatitis—Carmustine—hematologic cancer	5.24e-05	0.000405	CcSEcCtD
Loperamide—Vomiting—Alitretinoin—hematologic cancer	5.24e-05	0.000405	CcSEcCtD
Loperamide—Drowsiness—Doxorubicin—hematologic cancer	5.23e-05	0.000405	CcSEcCtD
Loperamide—Headache—Carmustine—hematologic cancer	5.21e-05	0.000403	CcSEcCtD
Loperamide—Rash—Alitretinoin—hematologic cancer	5.19e-05	0.000402	CcSEcCtD
Loperamide—Nervous system disorder—Betamethasone—hematologic cancer	5.19e-05	0.000402	CcSEcCtD
Loperamide—Nervous system disorder—Dexamethasone—hematologic cancer	5.19e-05	0.000402	CcSEcCtD
Loperamide—Dermatitis—Alitretinoin—hematologic cancer	5.19e-05	0.000402	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	5.18e-05	0.000401	CcSEcCtD
Loperamide—Vomiting—Ifosfamide—hematologic cancer	5.17e-05	0.000401	CcSEcCtD
Loperamide—Hypersensitivity—Cisplatin—hematologic cancer	5.17e-05	0.0004	CcSEcCtD
Loperamide—Headache—Alitretinoin—hematologic cancer	5.16e-05	0.000399	CcSEcCtD
Loperamide—Angioedema—Prednisone—hematologic cancer	5.16e-05	0.000399	CcSEcCtD
Loperamide—Diarrhoea—Gemcitabine—hematologic cancer	5.15e-05	0.000399	CcSEcCtD
Loperamide—Nausea—Thalidomide—hematologic cancer	5.14e-05	0.000398	CcSEcCtD
Loperamide—Dyspepsia—Triamcinolone—hematologic cancer	5.13e-05	0.000397	CcSEcCtD
Loperamide—Rash—Ifosfamide—hematologic cancer	5.13e-05	0.000397	CcSEcCtD
Loperamide—Dermatitis—Ifosfamide—hematologic cancer	5.13e-05	0.000397	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—hematologic cancer	5.12e-05	0.000397	CcSEcCtD
Loperamide—Dizziness—Irinotecan—hematologic cancer	5.11e-05	0.000396	CcSEcCtD
Loperamide—Urticaria—Etoposide—hematologic cancer	5.11e-05	0.000395	CcSEcCtD
Loperamide—Abdominal pain—Etoposide—hematologic cancer	5.08e-05	0.000393	CcSEcCtD
Loperamide—Vomiting—Vincristine—hematologic cancer	5.05e-05	0.000391	CcSEcCtD
Loperamide—Urticaria—Prednisolone—hematologic cancer	5.04e-05	0.00039	CcSEcCtD
Loperamide—Asthenia—Cisplatin—hematologic cancer	5.03e-05	0.00039	CcSEcCtD
Loperamide—Fatigue—Triamcinolone—hematologic cancer	5.03e-05	0.000389	CcSEcCtD
Loperamide—Urinary tract disorder—Epirubicin—hematologic cancer	5.01e-05	0.000388	CcSEcCtD
Loperamide—Rash—Vincristine—hematologic cancer	5e-05	0.000387	CcSEcCtD
Loperamide—Dermatitis—Vincristine—hematologic cancer	5e-05	0.000387	CcSEcCtD
Loperamide—Urethral disorder—Epirubicin—hematologic cancer	4.97e-05	0.000385	CcSEcCtD
Loperamide—Headache—Vincristine—hematologic cancer	4.97e-05	0.000385	CcSEcCtD
Loperamide—Loss of consciousness—Prednisone—hematologic cancer	4.96e-05	0.000384	CcSEcCtD
Loperamide—Nausea—Carmustine—hematologic cancer	4.94e-05	0.000382	CcSEcCtD
Loperamide—Vomiting—Mitoxantrone—hematologic cancer	4.91e-05	0.00038	CcSEcCtD
Loperamide—Vomiting—Irinotecan—hematologic cancer	4.91e-05	0.00038	CcSEcCtD
Loperamide—Immune system disorder—Methotrexate—hematologic cancer	4.89e-05	0.000379	CcSEcCtD
Loperamide—Nausea—Alitretinoin—hematologic cancer	4.89e-05	0.000379	CcSEcCtD
Loperamide—Rash—Mitoxantrone—hematologic cancer	4.87e-05	0.000377	CcSEcCtD
Loperamide—Rash—Irinotecan—hematologic cancer	4.87e-05	0.000377	CcSEcCtD
Loperamide—Dermatitis—Mitoxantrone—hematologic cancer	4.87e-05	0.000377	CcSEcCtD
Loperamide—Dermatitis—Irinotecan—hematologic cancer	4.87e-05	0.000377	CcSEcCtD
Loperamide—Clotrimazole—ABCB1—hematologic cancer	4.86e-05	0.0375	CrCbGaD
Loperamide—Headache—Irinotecan—hematologic cancer	4.84e-05	0.000375	CcSEcCtD
Loperamide—Headache—Mitoxantrone—hematologic cancer	4.84e-05	0.000375	CcSEcCtD
Loperamide—Nausea—Ifosfamide—hematologic cancer	4.83e-05	0.000374	CcSEcCtD
Loperamide—Diarrhoea—Cisplatin—hematologic cancer	4.8e-05	0.000372	CcSEcCtD
Loperamide—Erythema multiforme—Epirubicin—hematologic cancer	4.8e-05	0.000371	CcSEcCtD
Loperamide—Vomiting—Gemcitabine—hematologic cancer	4.79e-05	0.000371	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.77e-05	0.00037	CcSEcCtD
Loperamide—Discomfort—Prednisone—hematologic cancer	4.75e-05	0.000368	CcSEcCtD
Loperamide—Rash—Gemcitabine—hematologic cancer	4.75e-05	0.000367	CcSEcCtD
Loperamide—Dermatitis—Gemcitabine—hematologic cancer	4.74e-05	0.000367	CcSEcCtD
Loperamide—Hypersensitivity—Etoposide—hematologic cancer	4.74e-05	0.000367	CcSEcCtD
Loperamide—Headache—Gemcitabine—hematologic cancer	4.72e-05	0.000365	CcSEcCtD
Loperamide—Nausea—Vincristine—hematologic cancer	4.71e-05	0.000365	CcSEcCtD
Loperamide—Hypersensitivity—Prednisolone—hematologic cancer	4.67e-05	0.000362	CcSEcCtD
Loperamide—Dyspepsia—Dexamethasone—hematologic cancer	4.66e-05	0.000361	CcSEcCtD
Loperamide—Dyspepsia—Betamethasone—hematologic cancer	4.66e-05	0.000361	CcSEcCtD
Loperamide—Urinary tract disorder—Doxorubicin—hematologic cancer	4.63e-05	0.000359	CcSEcCtD
Loperamide—Urticaria—Triamcinolone—hematologic cancer	4.63e-05	0.000359	CcSEcCtD
Loperamide—Asthenia—Etoposide—hematologic cancer	4.61e-05	0.000357	CcSEcCtD
Loperamide—Anaphylactic shock—Prednisone—hematologic cancer	4.61e-05	0.000357	CcSEcCtD
Loperamide—Urethral disorder—Doxorubicin—hematologic cancer	4.6e-05	0.000356	CcSEcCtD
Loperamide—Nausea—Mitoxantrone—hematologic cancer	4.59e-05	0.000355	CcSEcCtD
Loperamide—Nausea—Irinotecan—hematologic cancer	4.59e-05	0.000355	CcSEcCtD
Loperamide—Immune system disorder—Epirubicin—hematologic cancer	4.58e-05	0.000355	CcSEcCtD
Loperamide—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.57e-05	0.000354	CcSEcCtD
Loperamide—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.57e-05	0.000354	CcSEcCtD
Loperamide—Fatigue—Dexamethasone—hematologic cancer	4.56e-05	0.000353	CcSEcCtD
Loperamide—Fatigue—Betamethasone—hematologic cancer	4.56e-05	0.000353	CcSEcCtD
Loperamide—Pruritus—Etoposide—hematologic cancer	4.55e-05	0.000352	CcSEcCtD
Loperamide—Nervous system disorder—Prednisone—hematologic cancer	4.52e-05	0.00035	CcSEcCtD
Loperamide—Skin disorder—Prednisone—hematologic cancer	4.47e-05	0.000346	CcSEcCtD
Loperamide—Nausea—Gemcitabine—hematologic cancer	4.47e-05	0.000346	CcSEcCtD
Loperamide—Vomiting—Cisplatin—hematologic cancer	4.46e-05	0.000345	CcSEcCtD
Loperamide—Erythema multiforme—Doxorubicin—hematologic cancer	4.44e-05	0.000344	CcSEcCtD
Loperamide—Rash—Cisplatin—hematologic cancer	4.42e-05	0.000343	CcSEcCtD
Loperamide—Dermatitis—Cisplatin—hematologic cancer	4.42e-05	0.000342	CcSEcCtD
Loperamide—Diarrhoea—Etoposide—hematologic cancer	4.4e-05	0.000341	CcSEcCtD
Loperamide—Haloperidol—ABCB1—hematologic cancer	4.38e-05	0.0338	CrCbGaD
Loperamide—Flatulence—Epirubicin—hematologic cancer	4.35e-05	0.000337	CcSEcCtD
Loperamide—Gastrointestinal pain—Betamethasone—hematologic cancer	4.33e-05	0.000335	CcSEcCtD
Loperamide—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.33e-05	0.000335	CcSEcCtD
Loperamide—Hypersensitivity—Triamcinolone—hematologic cancer	4.3e-05	0.000333	CcSEcCtD
Loperamide—Dizziness—Etoposide—hematologic cancer	4.25e-05	0.000329	CcSEcCtD
Loperamide—Immune system disorder—Doxorubicin—hematologic cancer	4.24e-05	0.000328	CcSEcCtD
Loperamide—Urticaria—Betamethasone—hematologic cancer	4.2e-05	0.000325	CcSEcCtD
Loperamide—Urticaria—Dexamethasone—hematologic cancer	4.2e-05	0.000325	CcSEcCtD
Loperamide—Dizziness—Prednisolone—hematologic cancer	4.19e-05	0.000325	CcSEcCtD
Loperamide—Asthenia—Triamcinolone—hematologic cancer	4.18e-05	0.000324	CcSEcCtD
Loperamide—Abdominal pain—Betamethasone—hematologic cancer	4.18e-05	0.000324	CcSEcCtD
Loperamide—Abdominal pain—Dexamethasone—hematologic cancer	4.18e-05	0.000324	CcSEcCtD
Loperamide—Nausea—Cisplatin—hematologic cancer	4.17e-05	0.000323	CcSEcCtD
Loperamide—Fentanyl—ABCB1—hematologic cancer	4.16e-05	0.0321	CrCbGaD
Loperamide—Pruritus—Triamcinolone—hematologic cancer	4.12e-05	0.000319	CcSEcCtD
Loperamide—Vomiting—Etoposide—hematologic cancer	4.09e-05	0.000316	CcSEcCtD
Loperamide—Dyspepsia—Prednisone—hematologic cancer	4.06e-05	0.000314	CcSEcCtD
Loperamide—Rash—Etoposide—hematologic cancer	4.05e-05	0.000314	CcSEcCtD
Loperamide—Dermatitis—Etoposide—hematologic cancer	4.05e-05	0.000314	CcSEcCtD
Loperamide—Headache—Etoposide—hematologic cancer	4.03e-05	0.000312	CcSEcCtD
Loperamide—Flatulence—Doxorubicin—hematologic cancer	4.03e-05	0.000312	CcSEcCtD
Loperamide—Rash—Prednisolone—hematologic cancer	4e-05	0.00031	CcSEcCtD
Loperamide—Dermatitis—Prednisolone—hematologic cancer	3.99e-05	0.000309	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.99e-05	0.000309	CcSEcCtD
Loperamide—Fatigue—Prednisone—hematologic cancer	3.97e-05	0.000308	CcSEcCtD
Loperamide—Headache—Prednisolone—hematologic cancer	3.97e-05	0.000308	CcSEcCtD
Loperamide—Discomfort—Methotrexate—hematologic cancer	3.97e-05	0.000307	CcSEcCtD
Loperamide—Constipation—Prednisone—hematologic cancer	3.94e-05	0.000305	CcSEcCtD
Loperamide—Loss of consciousness—Epirubicin—hematologic cancer	3.88e-05	0.0003	CcSEcCtD
Loperamide—Dizziness—Triamcinolone—hematologic cancer	3.86e-05	0.000299	CcSEcCtD
Loperamide—Anaphylactic shock—Methotrexate—hematologic cancer	3.85e-05	0.000298	CcSEcCtD
Loperamide—Nausea—Etoposide—hematologic cancer	3.82e-05	0.000296	CcSEcCtD
Loperamide—Asthenia—Betamethasone—hematologic cancer	3.8e-05	0.000294	CcSEcCtD
Loperamide—Asthenia—Dexamethasone—hematologic cancer	3.8e-05	0.000294	CcSEcCtD
Loperamide—Nervous system disorder—Methotrexate—hematologic cancer	3.78e-05	0.000292	CcSEcCtD
Loperamide—Gastrointestinal pain—Prednisone—hematologic cancer	3.77e-05	0.000292	CcSEcCtD
Loperamide—Nausea—Prednisolone—hematologic cancer	3.77e-05	0.000292	CcSEcCtD
Loperamide—Pruritus—Dexamethasone—hematologic cancer	3.74e-05	0.00029	CcSEcCtD
Loperamide—Pruritus—Betamethasone—hematologic cancer	3.74e-05	0.00029	CcSEcCtD
Loperamide—Skin disorder—Methotrexate—hematologic cancer	3.74e-05	0.00029	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.73e-05	0.000289	CcSEcCtD
Loperamide—Discomfort—Epirubicin—hematologic cancer	3.71e-05	0.000288	CcSEcCtD
Loperamide—Vomiting—Triamcinolone—hematologic cancer	3.71e-05	0.000287	CcSEcCtD
Loperamide—Rash—Triamcinolone—hematologic cancer	3.68e-05	0.000285	CcSEcCtD
Loperamide—Dry mouth—Epirubicin—hematologic cancer	3.68e-05	0.000285	CcSEcCtD
Loperamide—Dermatitis—Triamcinolone—hematologic cancer	3.67e-05	0.000284	CcSEcCtD
Loperamide—Urticaria—Prednisone—hematologic cancer	3.66e-05	0.000283	CcSEcCtD
Loperamide—Headache—Triamcinolone—hematologic cancer	3.65e-05	0.000283	CcSEcCtD
Loperamide—Abdominal pain—Prednisone—hematologic cancer	3.64e-05	0.000282	CcSEcCtD
Loperamide—Diarrhoea—Betamethasone—hematologic cancer	3.62e-05	0.00028	CcSEcCtD
Loperamide—Diarrhoea—Dexamethasone—hematologic cancer	3.62e-05	0.00028	CcSEcCtD
Loperamide—Anaphylactic shock—Epirubicin—hematologic cancer	3.6e-05	0.000279	CcSEcCtD
Loperamide—Loss of consciousness—Doxorubicin—hematologic cancer	3.59e-05	0.000278	CcSEcCtD
Loperamide—Nervous system disorder—Epirubicin—hematologic cancer	3.53e-05	0.000274	CcSEcCtD
Loperamide—Skin disorder—Epirubicin—hematologic cancer	3.5e-05	0.000271	CcSEcCtD
Loperamide—Dizziness—Betamethasone—hematologic cancer	3.5e-05	0.000271	CcSEcCtD
Loperamide—Dizziness—Dexamethasone—hematologic cancer	3.5e-05	0.000271	CcSEcCtD
Loperamide—Nausea—Triamcinolone—hematologic cancer	3.46e-05	0.000268	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.45e-05	0.000267	CcSEcCtD
Loperamide—Discomfort—Doxorubicin—hematologic cancer	3.44e-05	0.000266	CcSEcCtD
Loperamide—Somnolence—Methotrexate—hematologic cancer	3.42e-05	0.000265	CcSEcCtD
Loperamide—Dry mouth—Doxorubicin—hematologic cancer	3.4e-05	0.000263	CcSEcCtD
Loperamide—Hypersensitivity—Prednisone—hematologic cancer	3.39e-05	0.000263	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—hematologic cancer	3.39e-05	0.000262	CcSEcCtD
Loperamide—Vomiting—Betamethasone—hematologic cancer	3.36e-05	0.00026	CcSEcCtD
Loperamide—Vomiting—Dexamethasone—hematologic cancer	3.36e-05	0.00026	CcSEcCtD
Loperamide—Rash—Dexamethasone—hematologic cancer	3.34e-05	0.000258	CcSEcCtD
Loperamide—Rash—Betamethasone—hematologic cancer	3.34e-05	0.000258	CcSEcCtD
Loperamide—Anaphylactic shock—Doxorubicin—hematologic cancer	3.33e-05	0.000258	CcSEcCtD
Loperamide—Dermatitis—Dexamethasone—hematologic cancer	3.33e-05	0.000258	CcSEcCtD
Loperamide—Dermatitis—Betamethasone—hematologic cancer	3.33e-05	0.000258	CcSEcCtD
Loperamide—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.32e-05	0.000257	CcSEcCtD
Loperamide—Fatigue—Methotrexate—hematologic cancer	3.32e-05	0.000257	CcSEcCtD
Loperamide—Headache—Dexamethasone—hematologic cancer	3.31e-05	0.000257	CcSEcCtD
Loperamide—Headache—Betamethasone—hematologic cancer	3.31e-05	0.000257	CcSEcCtD
Loperamide—Asthenia—Prednisone—hematologic cancer	3.31e-05	0.000256	CcSEcCtD
Loperamide—Nervous system disorder—Doxorubicin—hematologic cancer	3.27e-05	0.000253	CcSEcCtD
Loperamide—Pruritus—Prednisone—hematologic cancer	3.26e-05	0.000252	CcSEcCtD
Loperamide—Skin disorder—Doxorubicin—hematologic cancer	3.24e-05	0.000251	CcSEcCtD
Loperamide—Somnolence—Epirubicin—hematologic cancer	3.2e-05	0.000248	CcSEcCtD
Loperamide—Dyspepsia—Epirubicin—hematologic cancer	3.17e-05	0.000246	CcSEcCtD
Loperamide—Diarrhoea—Prednisone—hematologic cancer	3.15e-05	0.000244	CcSEcCtD
Loperamide—Gastrointestinal pain—Methotrexate—hematologic cancer	3.15e-05	0.000244	CcSEcCtD
Loperamide—Nausea—Dexamethasone—hematologic cancer	3.14e-05	0.000243	CcSEcCtD
Loperamide—Nausea—Betamethasone—hematologic cancer	3.14e-05	0.000243	CcSEcCtD
Loperamide—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.11e-05	0.000241	CcSEcCtD
Loperamide—Fatigue—Epirubicin—hematologic cancer	3.11e-05	0.000241	CcSEcCtD
Loperamide—Constipation—Epirubicin—hematologic cancer	3.08e-05	0.000239	CcSEcCtD
Loperamide—Urticaria—Methotrexate—hematologic cancer	3.06e-05	0.000237	CcSEcCtD
Loperamide—Dizziness—Prednisone—hematologic cancer	3.05e-05	0.000236	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—hematologic cancer	3.04e-05	0.000236	CcSEcCtD
Loperamide—Somnolence—Doxorubicin—hematologic cancer	2.96e-05	0.000229	CcSEcCtD
Loperamide—Gastrointestinal pain—Epirubicin—hematologic cancer	2.95e-05	0.000228	CcSEcCtD
Loperamide—Dyspepsia—Doxorubicin—hematologic cancer	2.93e-05	0.000227	CcSEcCtD
Loperamide—Vomiting—Prednisone—hematologic cancer	2.93e-05	0.000227	CcSEcCtD
Loperamide—Rash—Prednisone—hematologic cancer	2.9e-05	0.000225	CcSEcCtD
Loperamide—Dermatitis—Prednisone—hematologic cancer	2.9e-05	0.000225	CcSEcCtD
Loperamide—Headache—Prednisone—hematologic cancer	2.89e-05	0.000223	CcSEcCtD
Loperamide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.88e-05	0.000223	CcSEcCtD
Loperamide—Tamoxifen—ABCB1—hematologic cancer	2.88e-05	0.0222	CrCbGaD
Loperamide—Fatigue—Doxorubicin—hematologic cancer	2.87e-05	0.000223	CcSEcCtD
Loperamide—Urticaria—Epirubicin—hematologic cancer	2.86e-05	0.000222	CcSEcCtD
Loperamide—Methadone—ABCB1—hematologic cancer	2.85e-05	0.022	CrCbGaD
Loperamide—Constipation—Doxorubicin—hematologic cancer	2.85e-05	0.000221	CcSEcCtD
Loperamide—Abdominal pain—Epirubicin—hematologic cancer	2.85e-05	0.000221	CcSEcCtD
Loperamide—Hypersensitivity—Methotrexate—hematologic cancer	2.84e-05	0.00022	CcSEcCtD
Loperamide—Asthenia—Methotrexate—hematologic cancer	2.76e-05	0.000214	CcSEcCtD
Loperamide—Nausea—Prednisone—hematologic cancer	2.74e-05	0.000212	CcSEcCtD
Loperamide—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.73e-05	0.000211	CcSEcCtD
Loperamide—Pruritus—Methotrexate—hematologic cancer	2.72e-05	0.000211	CcSEcCtD
Loperamide—Hypersensitivity—Epirubicin—hematologic cancer	2.65e-05	0.000206	CcSEcCtD
Loperamide—Urticaria—Doxorubicin—hematologic cancer	2.65e-05	0.000205	CcSEcCtD
Loperamide—Abdominal pain—Doxorubicin—hematologic cancer	2.64e-05	0.000204	CcSEcCtD
Loperamide—Diarrhoea—Methotrexate—hematologic cancer	2.63e-05	0.000204	CcSEcCtD
Loperamide—Asthenia—Epirubicin—hematologic cancer	2.59e-05	0.0002	CcSEcCtD
Loperamide—Pruritus—Epirubicin—hematologic cancer	2.55e-05	0.000197	CcSEcCtD
Loperamide—Dizziness—Methotrexate—hematologic cancer	2.55e-05	0.000197	CcSEcCtD
Loperamide—Diarrhoea—Epirubicin—hematologic cancer	2.47e-05	0.000191	CcSEcCtD
Loperamide—Hypersensitivity—Doxorubicin—hematologic cancer	2.46e-05	0.00019	CcSEcCtD
Loperamide—Vomiting—Methotrexate—hematologic cancer	2.45e-05	0.00019	CcSEcCtD
Loperamide—Rash—Methotrexate—hematologic cancer	2.43e-05	0.000188	CcSEcCtD
Loperamide—Dermatitis—Methotrexate—hematologic cancer	2.43e-05	0.000188	CcSEcCtD
Loperamide—Headache—Methotrexate—hematologic cancer	2.41e-05	0.000187	CcSEcCtD
Loperamide—Asthenia—Doxorubicin—hematologic cancer	2.39e-05	0.000185	CcSEcCtD
Loperamide—Dizziness—Epirubicin—hematologic cancer	2.38e-05	0.000184	CcSEcCtD
Loperamide—Pruritus—Doxorubicin—hematologic cancer	2.36e-05	0.000183	CcSEcCtD
Loperamide—Vomiting—Epirubicin—hematologic cancer	2.29e-05	0.000177	CcSEcCtD
Loperamide—Nausea—Methotrexate—hematologic cancer	2.29e-05	0.000177	CcSEcCtD
Loperamide—Diarrhoea—Doxorubicin—hematologic cancer	2.28e-05	0.000177	CcSEcCtD
Loperamide—Rash—Epirubicin—hematologic cancer	2.27e-05	0.000176	CcSEcCtD
Loperamide—Dermatitis—Epirubicin—hematologic cancer	2.27e-05	0.000176	CcSEcCtD
Loperamide—Headache—Epirubicin—hematologic cancer	2.26e-05	0.000175	CcSEcCtD
Loperamide—Dizziness—Doxorubicin—hematologic cancer	2.2e-05	0.000171	CcSEcCtD
Loperamide—Nausea—Epirubicin—hematologic cancer	2.14e-05	0.000166	CcSEcCtD
Loperamide—Vomiting—Doxorubicin—hematologic cancer	2.12e-05	0.000164	CcSEcCtD
Loperamide—Rash—Doxorubicin—hematologic cancer	2.1e-05	0.000163	CcSEcCtD
Loperamide—Dermatitis—Doxorubicin—hematologic cancer	2.1e-05	0.000163	CcSEcCtD
Loperamide—Headache—Doxorubicin—hematologic cancer	2.09e-05	0.000162	CcSEcCtD
Loperamide—Nausea—Doxorubicin—hematologic cancer	1.98e-05	0.000153	CcSEcCtD
Loperamide—CALM1—Disease—PTEN—hematologic cancer	1.11e-06	8.97e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CD—hematologic cancer	1.11e-06	8.97e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MAPK3—hematologic cancer	1.11e-06	8.97e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—NRAS—hematologic cancer	1.11e-06	8.97e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—BRAF—hematologic cancer	1.11e-06	8.92e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—BRAF—hematologic cancer	1.11e-06	8.92e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.1e-06	8.89e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ALB—hematologic cancer	1.1e-06	8.86e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—EP300—hematologic cancer	1.1e-06	8.85e-06	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—hematologic cancer	1.1e-06	8.85e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL2—hematologic cancer	1.1e-06	8.84e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL2—hematologic cancer	1.1e-06	8.84e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6R—hematologic cancer	1.09e-06	8.81e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6R—hematologic cancer	1.09e-06	8.81e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CREBBP—hematologic cancer	1.09e-06	8.8e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CREBBP—hematologic cancer	1.09e-06	8.8e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—PIK3CA—hematologic cancer	1.09e-06	8.76e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MYC—hematologic cancer	1.08e-06	8.72e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TGFB1—hematologic cancer	1.08e-06	8.7e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3CB—hematologic cancer	1.08e-06	8.7e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3CB—hematologic cancer	1.08e-06	8.7e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—STAT3—hematologic cancer	1.08e-06	8.69e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—STAT3—hematologic cancer	1.08e-06	8.69e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAP2K1—hematologic cancer	1.08e-06	8.68e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—NRAS—hematologic cancer	1.08e-06	8.67e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—NRAS—hematologic cancer	1.08e-06	8.67e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CD—hematologic cancer	1.07e-06	8.63e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—SRC—hematologic cancer	1.07e-06	8.6e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—MAPK3—hematologic cancer	1.07e-06	8.59e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—EP300—hematologic cancer	1.06e-06	8.56e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—EP300—hematologic cancer	1.06e-06	8.56e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TP53—hematologic cancer	1.05e-06	8.48e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3R1—hematologic cancer	1.05e-06	8.47e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—KRAS—hematologic cancer	1.05e-06	8.45e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAP2K1—hematologic cancer	1.04e-06	8.4e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAP2K1—hematologic cancer	1.04e-06	8.4e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.04e-06	8.38e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CD—hematologic cancer	1.04e-06	8.34e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CD—hematologic cancer	1.04e-06	8.34e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—SRC—hematologic cancer	1.03e-06	8.32e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—SRC—hematologic cancer	1.03e-06	8.32e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—MAPK3—hematologic cancer	1.03e-06	8.31e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—MAPK3—hematologic cancer	1.03e-06	8.31e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—STAT3—hematologic cancer	1.03e-06	8.3e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—NRAS—hematologic cancer	1.03e-06	8.28e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—FGF2—hematologic cancer	1.03e-06	8.26e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—CREBBP—hematologic cancer	1.02e-06	8.25e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—KRAS—hematologic cancer	1.01e-06	8.17e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—KRAS—hematologic cancer	1.01e-06	8.17e-06	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—AKT1—hematologic cancer	1.01e-06	8.16e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3R1—hematologic cancer	1.01e-06	8.15e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HRAS—hematologic cancer	1.01e-06	8.11e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—KRAS—hematologic cancer	1e-06	8.06e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTP1—hematologic cancer	9.97e-07	8.03e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—STAT3—hematologic cancer	9.97e-07	8.03e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—STAT3—hematologic cancer	9.97e-07	8.03e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—NRAS—hematologic cancer	9.94e-07	8.01e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—NRAS—hematologic cancer	9.94e-07	8.01e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—FGF2—hematologic cancer	9.92e-07	7.99e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—FGF2—hematologic cancer	9.92e-07	7.99e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PTEN—hematologic cancer	9.91e-07	7.98e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—MAPK3—hematologic cancer	9.84e-07	7.93e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—JAK2—hematologic cancer	9.83e-07	7.92e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3R1—hematologic cancer	9.78e-07	7.88e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3R1—hematologic cancer	9.78e-07	7.88e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CB—hematologic cancer	9.71e-07	7.82e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CD—hematologic cancer	9.71e-07	7.82e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—CREBBP—hematologic cancer	9.65e-07	7.77e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PTEN—hematologic cancer	9.65e-07	7.77e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—PIK3CA—hematologic cancer	9.64e-07	7.76e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—hematologic cancer	9.63e-07	7.76e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MDM2—hematologic cancer	9.6e-07	7.73e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ALB—hematologic cancer	9.58e-07	7.72e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—KRAS—hematologic cancer	9.58e-07	7.72e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—MYC—hematologic cancer	9.57e-07	7.71e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—TGFB1—hematologic cancer	9.55e-07	7.69e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—MAPK3—hematologic cancer	9.52e-07	7.67e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—MAPK3—hematologic cancer	9.52e-07	7.67e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—JAK2—hematologic cancer	9.51e-07	7.66e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—JAK2—hematologic cancer	9.51e-07	7.66e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—EP300—hematologic cancer	9.46e-07	7.61e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ABCB1—hematologic cancer	9.44e-07	7.6e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MTOR—hematologic cancer	9.34e-07	7.52e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CB—hematologic cancer	9.34e-07	7.52e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PTEN—hematologic cancer	9.33e-07	7.52e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PTEN—hematologic cancer	9.33e-07	7.52e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—PIK3CA—hematologic cancer	9.32e-07	7.51e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—PIK3CA—hematologic cancer	9.32e-07	7.51e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MDM2—hematologic cancer	9.28e-07	7.48e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MDM2—hematologic cancer	9.28e-07	7.48e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—KRAS—hematologic cancer	9.27e-07	7.46e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—KRAS—hematologic cancer	9.27e-07	7.46e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—MYC—hematologic cancer	9.26e-07	7.46e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—MYC—hematologic cancer	9.26e-07	7.46e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—TGFB1—hematologic cancer	9.24e-07	7.44e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—TGFB1—hematologic cancer	9.24e-07	7.44e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—EP300—hematologic cancer	9.2e-07	7.41e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—PIK3CA—hematologic cancer	9.2e-07	7.4e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3R1—hematologic cancer	9.17e-07	7.38e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—GSTM1—hematologic cancer	9.16e-07	7.38e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—NCOR1—hematologic cancer	9.16e-07	7.38e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CD—hematologic cancer	9.15e-07	7.37e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CB—hematologic cancer	9.03e-07	7.27e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CB—hematologic cancer	9.03e-07	7.27e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MTOR—hematologic cancer	9.03e-07	7.27e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MTOR—hematologic cancer	9.03e-07	7.27e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ALB—hematologic cancer	9.03e-07	7.27e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HRAS—hematologic cancer	8.91e-07	7.18e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—EP300—hematologic cancer	8.9e-07	7.17e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—EP300—hematologic cancer	8.9e-07	7.17e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TP53—hematologic cancer	8.9e-07	7.16e-06	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—AKT1—hematologic cancer	8.89e-07	7.16e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—KRAS—hematologic cancer	8.85e-07	7.12e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—PIK3CA—hematologic cancer	8.8e-07	7.09e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDKN1B—hematologic cancer	8.76e-07	7.06e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3R1—hematologic cancer	8.64e-07	6.96e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HRAS—hematologic cancer	8.62e-07	6.94e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HRAS—hematologic cancer	8.62e-07	6.94e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CASP3—hematologic cancer	8.59e-07	6.92e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL2—hematologic cancer	8.57e-07	6.9e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—KRAS—hematologic cancer	8.56e-07	6.89e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—KRAS—hematologic cancer	8.56e-07	6.89e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—hematologic cancer	8.53e-07	6.87e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—PIK3CA—hematologic cancer	8.52e-07	6.86e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—PIK3CA—hematologic cancer	8.52e-07	6.86e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HRAS—hematologic cancer	8.51e-07	6.85e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN1B—hematologic cancer	8.48e-07	6.83e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN1B—hematologic cancer	8.48e-07	6.83e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CB—hematologic cancer	8.46e-07	6.81e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PTEN—hematologic cancer	8.39e-07	6.76e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCND1—hematologic cancer	8.36e-07	6.73e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—JUN—hematologic cancer	8.34e-07	6.72e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CASP3—hematologic cancer	8.31e-07	6.69e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CASP3—hematologic cancer	8.31e-07	6.69e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL2—hematologic cancer	8.29e-07	6.68e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL2—hematologic cancer	8.29e-07	6.68e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—hematologic cancer	8.25e-07	6.65e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—hematologic cancer	8.25e-07	6.65e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—HRAS—hematologic cancer	8.14e-07	6.56e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—hematologic cancer	8.14e-07	6.56e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—PIK3CA—hematologic cancer	8.13e-07	6.55e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—MTHFR—hematologic cancer	8.1e-07	6.52e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CDKN1A—hematologic cancer	8.09e-07	6.51e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCND1—hematologic cancer	8.09e-07	6.51e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCND1—hematologic cancer	8.09e-07	6.51e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—JUN—hematologic cancer	8.07e-07	6.5e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—JUN—hematologic cancer	8.07e-07	6.5e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PTEN—hematologic cancer	8.07e-07	6.5e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—EP300—hematologic cancer	8e-07	6.45e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CB—hematologic cancer	7.97e-07	6.42e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAPK8—hematologic cancer	7.89e-07	6.36e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—HRAS—hematologic cancer	7.88e-07	6.34e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—HRAS—hematologic cancer	7.88e-07	6.34e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—AKT1—hematologic cancer	7.87e-07	6.34e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—PIK3CA—hematologic cancer	7.86e-07	6.33e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—PIK3CA—hematologic cancer	7.86e-07	6.33e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CDKN1A—hematologic cancer	7.82e-07	6.3e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CDKN1A—hematologic cancer	7.82e-07	6.3e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PTEN—hematologic cancer	7.8e-07	6.28e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PTEN—hematologic cancer	7.8e-07	6.28e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—hematologic cancer	7.8e-07	6.28e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—EP300—hematologic cancer	7.69e-07	6.2e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAPK8—hematologic cancer	7.64e-07	6.15e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAPK8—hematologic cancer	7.64e-07	6.15e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—AKT1—hematologic cancer	7.61e-07	6.13e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—AKT1—hematologic cancer	7.61e-07	6.13e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—hematologic cancer	7.54e-07	6.07e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—hematologic cancer	7.54e-07	6.07e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—HRAS—hematologic cancer	7.52e-07	6.06e-06	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—AKT1—hematologic cancer	7.51e-07	6.05e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SRC—hematologic cancer	7.48e-07	6.03e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—EP300—hematologic cancer	7.44e-07	5.99e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—EP300—hematologic cancer	7.44e-07	5.99e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PTEN—hematologic cancer	7.31e-07	5.89e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—VEGFA—hematologic cancer	7.29e-07	5.87e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—HRAS—hematologic cancer	7.27e-07	5.86e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—HRAS—hematologic cancer	7.27e-07	5.86e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SRC—hematologic cancer	7.24e-07	5.83e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SRC—hematologic cancer	7.24e-07	5.83e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—STAT3—hematologic cancer	7.22e-07	5.81e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—NRAS—hematologic cancer	7.2e-07	5.8e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—hematologic cancer	7.2e-07	5.8e-06	CbGpPWpGaD
Loperamide—CALM3—Immune System—AKT1—hematologic cancer	7.19e-07	5.79e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—VEGFA—hematologic cancer	7.05e-07	5.68e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—VEGFA—hematologic cancer	7.05e-07	5.68e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—PIK3CA—hematologic cancer	6.99e-07	5.63e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—STAT3—hematologic cancer	6.98e-07	5.62e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—STAT3—hematologic cancer	6.98e-07	5.62e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—EP300—hematologic cancer	6.97e-07	5.62e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—NRAS—hematologic cancer	6.96e-07	5.61e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—NRAS—hematologic cancer	6.96e-07	5.61e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—hematologic cancer	6.96e-07	5.61e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—hematologic cancer	6.96e-07	5.61e-06	CbGpPWpGaD
Loperamide—CALM2—Immune System—AKT1—hematologic cancer	6.96e-07	5.6e-06	CbGpPWpGaD
Loperamide—CALM1—Immune System—AKT1—hematologic cancer	6.96e-07	5.6e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAPK3—hematologic cancer	6.89e-07	5.55e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PTEN—hematologic cancer	6.89e-07	5.55e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—PIK3CA—hematologic cancer	6.81e-07	5.48e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CG—hematologic cancer	6.8e-07	5.48e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MYC—hematologic cancer	6.7e-07	5.4e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TGFB1—hematologic cancer	6.69e-07	5.39e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAPK3—hematologic cancer	6.67e-07	5.37e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAPK3—hematologic cancer	6.67e-07	5.37e-06	CbGpPWpGaD
Loperamide—CALM3—Disease—AKT1—hematologic cancer	6.64e-07	5.35e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—PIK3CA—hematologic cancer	6.58e-07	5.3e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—PIK3CA—hematologic cancer	6.58e-07	5.3e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—EP300—hematologic cancer	6.57e-07	5.29e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MYC—hematologic cancer	6.49e-07	5.22e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MYC—hematologic cancer	6.49e-07	5.22e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TGFB1—hematologic cancer	6.47e-07	5.21e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TGFB1—hematologic cancer	6.47e-07	5.21e-06	CbGpPWpGaD
Loperamide—CALM2—Disease—AKT1—hematologic cancer	6.42e-07	5.17e-06	CbGpPWpGaD
Loperamide—CALM1—Disease—AKT1—hematologic cancer	6.42e-07	5.17e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—CREBBP—hematologic cancer	6.31e-07	5.08e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—KRAS—hematologic cancer	6.2e-07	4.99e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—KRAS—hematologic cancer	5.99e-07	4.83e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—KRAS—hematologic cancer	5.99e-07	4.83e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.98e-07	4.82e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—PIK3CA—hematologic cancer	5.92e-07	4.77e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ALB—hematologic cancer	5.9e-07	4.75e-06	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—AKT1—hematologic cancer	5.71e-07	4.6e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—PIK3CA—hematologic cancer	5.69e-07	4.58e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3R1—hematologic cancer	5.65e-07	4.55e-06	CbGpPWpGaD
Loperamide—CALM3—Metabolism—AKT1—hematologic cancer	5.56e-07	4.48e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TP53—hematologic cancer	5.51e-07	4.43e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PIK3CA—hematologic cancer	5.51e-07	4.43e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PIK3CA—hematologic cancer	5.51e-07	4.43e-06	CbGpPWpGaD
Loperamide—CALM2—Metabolism—AKT1—hematologic cancer	5.38e-07	4.33e-06	CbGpPWpGaD
Loperamide—CALM1—Metabolism—AKT1—hematologic cancer	5.38e-07	4.33e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TP53—hematologic cancer	5.33e-07	4.29e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TP53—hematologic cancer	5.33e-07	4.29e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HRAS—hematologic cancer	5.27e-07	4.24e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CB—hematologic cancer	5.21e-07	4.2e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—PIK3CA—hematologic cancer	5.16e-07	4.15e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HRAS—hematologic cancer	5.09e-07	4.1e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HRAS—hematologic cancer	5.09e-07	4.1e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—hematologic cancer	5.04e-07	4.06e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—hematologic cancer	4.88e-07	3.93e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—hematologic cancer	4.88e-07	3.93e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—PIK3CA—hematologic cancer	4.86e-07	3.91e-06	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—AKT1—hematologic cancer	4.84e-07	3.9e-06	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—AKT1—hematologic cancer	4.65e-07	3.74e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PTEN—hematologic cancer	4.51e-07	3.63e-06	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—AKT1—hematologic cancer	4.5e-07	3.62e-06	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—AKT1—hematologic cancer	4.5e-07	3.62e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—EP300—hematologic cancer	4.3e-07	3.46e-06	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AKT1—hematologic cancer	4.21e-07	3.39e-06	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AKT1—hematologic cancer	3.97e-07	3.2e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—PIK3CA—hematologic cancer	3.18e-07	2.56e-06	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AKT1—hematologic cancer	2.6e-07	2.09e-06	CbGpPWpGaD
